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Abstract 
Endothelin-I (ET-1) binding to human astrocytoma U138MG cells was time-dependent, and bound [125I]ET-1 was difficult to 
dissociate. The Bma x and K d values of [125I]ET-1 binding were 70 fmol/mg and 0.07 nM, respectively. Interestingly, different from 
other astrocytoma cells and astrocytes, the U138MG cells expressed predominantly ET A receptor as shown by RT-PCR results and 
binding studies. ET-1, FR139317, BQ123, PD142893 and Ro46-2005 inhibited specific [125I]ET-1 binding with K i values of 0.10, 0.53, 
4.3, 22, and 320 nM, respectively. ET B selective ligands ET-3 and IRL1620 were much less potent. The inhibitory effects of antagonists 
BQ123 and PD142893 on [125I]ET-1 binding diminished following the incubation time. ET-1 binding caused a modest stimulation in 
phosphatidylinositol hydrolysis with an ECs0 value of 24 nM. In comparison to the human U373MG cells, ET-l-induced receptor 
internalization in U138MG cells was less efficient with 42% of bound ET-1 internalized after 30 min of incubation. These results imply 
that human astrocytoma cells/astrocytes are able to express either ET A or ET B receptor under different pathophysiological conditions. 
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I.  Introduct ion 
Endothelin (ET), originally isolated from cultured 
porcine aortic endothelial cells, is a highly potent vasocon- 
stricting peptide with 21 amino acid residues [1]. Three 
distinct members of  the ET family, namely, ET-1, ET-2 
and ET-3, have been identified in humans through cloning 
[2]. ET has been shown to play important roles in the 
cardiovascular system, the renal system, and the central 
nervous system [3,4]. The effects of  ETs on mammalian 
organs and cells are initiated by their binding to membrane 
receptors. High-affinity receptors specific for ET are found 
in various tissues and cells, such as brain, lung, and 
mesangial cells [5]. Two types of  mammalian ET recep- 
tors, ET A and ET B, have been characterized, purified [6,7] 
and their cDNA have been cloned [8,9]. ET A receptors are 
selective for ET-1 and ET-2, while ET B receptors bind to 
Abbreviations: ET, endothelin; Gpp(NH)p, 
dodiphosphate. 
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ET-1, ET-2 and ET-3 with equal potency. Several antago- 
nists and agonists for ET receptors have been developed. 
Among them, BQ123 and FR139317 are selective antago- 
nists for ET A receptors; PD142893 and Ro46-2005 antago- 
nize both ET A and ET B receptors [10]. 
In the CNS, glial cells can be generally classified into 
two major classes, called oligodendrocytes and astrocytes. 
The oligodendrocytes wrap around the axons to form an 
insulating myelin sheath. Although astrocytes are the ma- 
jor cell type in the brain, their functions are less clear. It 
has been proposed that the glial cells, especially the astro- 
cytes, not only play nurturing roles to the neurons, but also 
help in maintaining neurons' signaling capacity by clean- 
ing up the neuronal environment. This latter function is 
important because neurotransmitters and other substances, 
once released into synapses, can interfere with subsequent 
neuronal activity if not removed quickly. 
The role of  ET in the CNS has been under considerable 
investigation since the discovery of  ET in 1988 [11]. ET is 
synthesized by neurons, and has been proposed as an 
intracellular messenger, either directly as a neurotrans- 
mitter or as a neuromodulator [11]. ET receptor and ET 
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have been identified in the brain [12]. ET released as a 
result of neuronal injury seems to initiate astrocyte prolif- 
eration and the concomitant increase in potassium buffer- 
ing [13]. In addition, it has been shown that ET induces the 
differentiated astrocytes to become proliferative [14]. 
High-affinity binding sites for ET with ET B characteristics 
have been found in astrocytes and astrocytoma cells from 
rats or mice [14-18]. Previously we have also found that 
the human astrocytoma U373MG cells express predomi- 
nantly the ET B receptor, consistent with results using 
astrocytes of animal origin [19]. However, in contrast to 
astrocytes from rats or mice in which ET binding evokes 
phosphoinositide breakdown, Ca 2+ influx, and the release 
of arachidonic acid, we found that in U373MG cells ET 
binding does not stimulate Ca 2+ mobilization, arachidonic 
acid release, phosphoinositide breakdown, and also does 
not exert any effect on the intracellular cAMP or cGMP 
level. Instead, ET B receptor in U373MG cells is rather 
efficient in internalizing bound ET, suggesting that ET B 
receptor in human astrocytes may be involved in clearing 
ET by ligand-induced receptor internalization. This finding 
supports the idea that the astrocytes play a role in main- 
taining neurons' signaling capacity by cleaning up neuro- 
transmitters and/or  neuromodulators such as ET in the 
synapses. It is important to note that, so far, studies using 
cultured cells have shown that astrocytoma cells/astro- 
cytes express mainly ET B receptor, consistent with the 
finding that ET B receptor seems to be the predominant 
receptor type in the neuronal or glial tissues of normal 
human brains. Therefore, it is surprising that, by RT-PCR 
and binding studies, we found that the human astrocytoma 
U138MG cells expressed predominantly the ET A receptor. 
Receptor internalization induced by ligand binding in 
U138MG cells was less efficient than that in U373MG 
cells, and ET-1 binding stimulated phosphatidylinositol 
hydrolysis. Our results suggest that human astrocytoma 
cells, and/or  perhaps human astrocytes, are able to ex- 
press either ET A or ET B receptor, possibly dependent upon 
the pathophysiological conditions. 
2. Materials and methods 
2.1. Materials 
[~25I]ET-1 (2200 Ci/mmol) was obtained from Du 
Pont, NEN (Boston, MA). ET-1 and ET-3 were purchased 
from American Peptide Company, Sunnyvale, CA. BQ123 
(cyclo[D-Trp-D-Asp-Pro-D-Val-Leu]), FR139317 ((R)2- 
[( R )-2-[(S)-2-[ 1 -(hexahydro- 1H-azepinyl)]carbonyl]amino- 
4-methylpentanoyl]amino-3-[3-(1-methyl- 1H-indoyl)]pro- 
pionyl]amino-3-(2-pyridyl)propionic acid), Ro46-2005 (4- 
tert-butyl-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)- 
4-pyrimidinyl]-benzenesulphonamide), PD142893 (Ac-o- 
diphenylalanine-Leu-Asp-Ile-Ile-Trp), and IRL1620 (Suc- 
[Glu 9,Ala I l. 15 ]-ET (8-21)) were synthesized in-house. Other 
reagents were of analytical grade. 
2.2. Cell culture 
U138MG cells were obtained from American Type 
Culture Collection (Rockville, MD) and were grown in 
Dulbecco's modified minimal essential medium (DMEM) 
containing 10% fetal bovine serum (Gibco) as previously 
described [19]. Cell viability was examined by the trypan 
blue exclusion method. 
2.3. Preparation o f  membranes f rom cells 
Cells ( ~ 90% confluency) from four T150 culture flasks 
were collected by scraping, centrifugation (1000 × g for 
10 min) and then homogenized in 25 ml of 10 mM Hepes 
(pH 7.4) containing 0.25 M sucrose and protease inhibitors 
(50 mM EDTA, 0.1 mM PMSF, and 5 /xg/ml Pepstatin 
A) by a micro ultrasonic cell disruptor (Kontes). The 
mixture was centrifuged at 1000 × g for 10 min. The 
supernatant was collected and centrifuged at 60000 × g 
for 60 min. The precipitate was resuspended in Buffer B 
(20 mM Tris, 100 mM NaCI, 10 mM MgC12, pH 7.4) 
containing the aforementioned protease inhibitors and cen- 
trifuged again. The final pellet was resuspended in Buffer 
B containing protease inhibitors and stored at - 80°C until 
used. Protein content was determined by the Bio-Rad 
dye-binding protein assay. 
2.4. [1251]ET-1 binding to membranes or cells 
Binding assays were performed in 96-well microtiter 
plates pretreated with 0.1% BSA. Membranes prepared 
from cells were diluted in Buffer B-1 (Buffer B with 0.2% 
BSA and 50 mM EDTA, 0.1 mM PMSF, 0.025% baci- 
tracin, and 5 /zg/ml Pepstatin A) to a final concentration 
of 0.1 or 0.2 mg/ml  of protein. In competition studies, 
membranes were incubated with 0.1 nM of [125I]ET-1 in 
Buffer B-1 (final volume: 0.2 ml) in the presence of 
increasing concentrations of unlabeled test ligands for 3 h 
at 25°C. In saturation studies, membranes were incubated 
with various concentrations of [125I]ET-1 for 4 h at 25°C. 
In experiments using intact cells, cells ( ~  90% conflu- 
ency) in T150 culture flasks were washed by PBS before 
being scraped into Buffer A (Earle's solution: 140 mM 
NaC1, 5 mM KC1, 1.8 mM CaC12, 0.8 mM MgSO 4, 5 mM 
glucose, buffered with 25 mM Hepes, pH 7.4) containing 
protease inhibitors (5 /zg/ml pepstatin A, 0.01 mM phos- 
phoramidon, 0.01 mM PMSF). Binding assays were per- 
formed for 4 h at 4°C as described above. After the 
incubation, unbound ligands were separated from bound 
ligands by vacuum filtration using glass-fiber filter strips 
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in PHD TM cell harvesters (Cambridge Technology, Inc., 
MA), followed by washing the filter strips with saline (1 
ml) for three times. Non-specific binding was determined 
in the presence of 1 /zM ET-1. 
2.5. RNA isolation 
Total RNA was isolated from U138MG human astrocy- 
toma cells and human placenta by the guanidinium thio- 
cyanate/phenol chloroforrn extraction method [20]. Sam- 
ples were separated by electrophoresis in agarose/formal- 
dehyde gels to assess quality and OD260/280 values were 
measured to estimate quantity. 
2.6. Reverse transcription-polymerase chain reaction (RT- 
PCR) 
The RT-PCR was performed using a GeneAmp RNA 
PCR kit (Perkin Elmer Cetus) according to the manufac- 
turer's instructions. Briefly, 1.0 /zg of U138MG or pla- 
centa total RNA was rever,;e-transcribed using the random 
hexamer primers. The cDNA was then amplified for 35 
cycles using ET a or ET B sets of primers. Each cycle 
consisted of 95 °, 1 min (denature), 60 °, 1 min (anneal), and 
72 °, 2 min (extend). The primer sets, based on published 
sequences of human ET a and ET B receptors, were synthe- 
sized in house. Set 1 (ETA): 5'-GATCACAATGACTTTG- 
GCGTATTTC-3'  and 5'-CTCAAGCTGCCATTCCT- 
TCTGTTC-3'. Set 2 (ETs): 5'-CTAAAGGAGACAG- 
GACGGCAGGATC-3' and 5'-GATTCGCAGATAACT- 
TCCTTTGTAG-3'. The RT-PCR samples were analyzed 
by standard agarose gel electrophoresis. 
2.7. Measurement of PI hydrolysis 
Cells in 48-well culture plates were labeled with 1 
/xCi/well of myo-[3H]inositol in DMEM for 16-24 h. 
Cells were washed with PBS, then incubated with Buffer 
A containing protease inhibitors (as described above) and 
10 mM LiC1 for 60 min before being challenged with 
ET-1. ET challenge was terminated by the addition of 50 
/zl of 1 N NaOH, and the mixture was immediately 
neutralized by adding 50 /xl of 1 N HC1. The samples 
were treated with 1.5 ml of chloroform/methanol (1:2, 
v /v) .  Total inositol phosphates were extracted after adding 
chloroform and water to give final proportions of chloro- 
form/methanol/water  of 1:1:0.9 (v /v )  as described by 
Berridge et al. [21]. The upper aqueous phase (1 ml) was 
retained and a small portion (100 /zl) counted. The rest of 
the aqueous sample was analyzed by batch chromatog- 
raphy using the anion-exchange resin AG1-X8 (Bio-Rad). 
Total water-solnhle inositcl phosphates were eluted from 
the resin by 6 ml of 1 M ammonium formate with 0.1 N 
formic acid after the resin was washed with 6 ml of 60 
mM sodium formate with 5 mM sodim tetraborate. 
2.8. Measurement of the intracellular cAMP concentration 
Cells in 48-well culture plates were washed with PBS 
once, and then incubated with 0.2 ml of Buffer A contain- 
ing protease inhibitors (as described above) and 0.5 mM 
isobutylmethylxanthine for 10 min before being challenged 
with ET and/or  isoproterenol or forskolin for 15 min at 
37°C. ET challenge was terminated by the addition of 200 
/zl of 0.2 N HC1, and the mixture was immediately acety- 
lated by adding 20 /xl of acetic anhydride and trieth- 
ylamine (1:2.5, v /v) .  The concentration of cAMP was 
determined by RIA, using the automated Attoflo system 
(Rockville, MD) as previously described [22]. 
2.9. Receptor internalization 
To study receptor internalization, cells in 48-well cul- 
ture plates were incubated with 0.1 nM [125I]ET-1 in 0.2 
ml DMEM with 10% fetal bovine serum for different 
periods of time at 37°C or 4°C, washed with 0.5 ml 
ice-cold PBS, and then treated with 0.5 ml of ice-cold 0.2 
M acetic acid and 0.5 M NaC1 (pH 2.5) at 4°C for 20 min 
to remove the surface-bound radiolabeled ligand [23]. The 
remaining cell-associated radioactivity (the internalized 
[125I]ET-1) was determined by solubilizing cells in 0.5 ml 
of 0.1 N NaOH. 
3. Results 
Fig. 1 shows that ET-1 binding to membranes prepared 
from the U138MG cells was time-dependent and reached a 
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Fig. 1. Time course studies. Membranes (0.01 mg) were incubated with 
0.1 nM []zSI]ET-I for different periods of time at 25°C (total binding, 
0 ) .  At time 0, 1 /xM of ET-1 was added (non-specific binding, O). 
After 4 h of incubation, 1 ~M unlabeled Ro46-2005 (rq) or 1 ~M 
ET-1 + 100 /~M Gpp(NH)p ( * )  was added. Specific binding ( 0 )  was 
calculated by subtracting non-specific (O)  binding from total binding 
(0 ) .  Each value represents the mean+S.D, of 3 determinations. The 
dotted line indicates the amount of bound [t25I]ET-1 at 4 h. 
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plateau after 4 h of incubation. Addition of 1 /xM ET-1 at 
time zero blocked a majority of []25I]ET-1 binding ( ~  60% 
after 6 h of incubation). However, adding 1 /zM ET-1 plus 
100/xM Gpp(NH)p ((5'-)guanylylimidodiphosphate) at 4 h 
dissociated bound [t25I]ET-1 by < 15%. Similarly, addi- 
tion of 50/zM Ro46-2005 at 4 h failed to dissociate bound 
[]25I]ET-1. Previously we have shown that ET-1 binding to 
ET B receptor in porcine cerebellum or U373MG cells is of 
high affinity and bound ET-1 is difficult to dissociate [19]. 
The current observation shows that the U138MG cells 
contain ET receptors and bound ET-1 to the receptor is 
also difficult to dissociate. 
The number of ET binding sites in U138MG cells was 
then determined. Fig. 2A shows that, in membranes pre- 
pared from U138MG cells, [¿25I]ET-1 binding reached a 
plateau at 0.2 nM ET-1. The results were analyzed by the 
radioligand binding analysis program 'EBDA and LIG- 
AND' (Biosoft, MO, USA). Scatchard analysis (Fig. 2B) 
yielded a straight line with values of Bma x and K d at 70 
fmol /mg and 0.07 nM, respectively. The Hill coefficient 
was calculated to be 1.005. When intact cells were used in 
similar experiments with the incubation done at 4°C for 4 
h, values of Bma x and Kd were determined to be 46.2 
fmol/1 × 10 6 cells and 0.20 nM, respectively (not shown). 
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Fig, 2. Saturation studies. (A) Membranes (0.025 mg) were incubated 
with increasing concentrations of [125I]ET-I in the absence ( 0 )  or 
presence (C)) of 1 /zM unlabeled ET-1 for 4 h at 25°C. Specific binding 
(zx) was determined by subtraction of non-specific binding ((3) from 
total binding (O).  Each value represents the mean +_ S.D. of 3 determina- 
tions. (B) Scatchard analysis for (A). 
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Fig. 3. Competition studies. (A) Cells (0.4X106 cells/well) or (B) 
Membranes (0.02 mg) were incubated with 0.1 nM [I25I]ET-1 in the 
presence of increasing concentrations of unlabeled ligands for (A) 4h at 
4°C or (B) 4 h at 25°C. Results are expressed as % of control (specific 
binding in the absence of unlabeled ligand). Non-specific binding, deter- 
mined in the presence of 1 /xM of ET-1 was subtracted from total binding 
to give specific binding. Each value represents the mean+_S.D, of 3 
determinations. 
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The Hill coefficient was calculated to be 0.97. In these 
cells, the protein content in membranes prepared from 
1 × 10 6 cells was approximately 0.6 mg. The number of 
receptors was calculated to be 27 810 sites per cell. 
Fig. 3 shows the results from competition studies in 
which various ET receptor ligands were used to compete 
against [125I]ET-1 binding. Fig. 3A shows that, in intact 
cells, unlabeled ET-1 effectively inhibited specific 
[125I]ET-1 binding (ICs0 = 0.5 nM). ET B selective ligand 
ET-3 was much less effective in inhibiting specific 
[125I]ET-1 binding with an ICs0 value of 400 nM. To 
compare various agonists and antagonists, membranes pre- 
pared from cells were used. Fig. 3B shows that unlabeled 
ET-1 effectively inhibited specific [ 125 I]ET-1 binding (IC 5o 
--0.12 nM). IRL1620, a partial agonist selective for ET B 
receptor, was not potent in inhibiting [~25I]ET-1 binding 
(ICs0 = 1730 nM). Among various ET receptor antago- 
nists, Ro46-2005 and PD142893, two non-selective antag- 
onists, abolished specific [~zSI]ET-1 binding with ICso 
values of 479 and 37 nM, respectively. FR139317 and 
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BQ123, two ET A selective antagonists, were potent with 
IC50 values of 1.09 and 9.4:8 nM, respectively. The radioli- 
gand binding analysis program 'EBDA and LIGAND' 
(Biosoft, MO, USA) was used to analyze data for the 
calculation of IC5o and K i. A summary of the IC50 and K i 
values is shown in Table 1. These results suggest that 
U138MG cells contain predominantly ET A receptor. 
To further examine if UI38MG cells expressed pre- 
dominantly ET A receptor, RT-PCR experiments were per- 
formed (Fig. 4). When primers for the ET A receptor (Set 1, 
as described in Section 2) were used with total RNA from 
U138MG cells, a specific' DNA band migrating at the 
expected size of 427 bp was observed (Lane 2). This 
fragment was subsequently isolated, cloned, and se- 
quenced, verifying that the PCR product was derived from 
human ET A receptor (data not shown). No DNA band 
could be detected when the primer was omitted or when 
the reverse transcriptase was omitted from the reaction 
mixture (Lanes 4 and 5). Ii1 contrast, when primers for the 
ET B receptor (Set 2) were used, no specific DNA band 
could be detected (Lane 6). Control experiments using 
total RNA prepared from human placenta show specific 
DNA bands migrating at the expected sizes of 427 bp (Set 
1) and 547 bp (Set 2) for ]ET A and ET B receptors, respec- 
tively (Lanes 3 and 7). Pn~viously it has been shown that 
human placenta expresses both ET A and ET B receptor [24]. 
These results are consistent with the binding studies that 
U138MG cells express predominantly ET A receptor. 
Previously we have shown that bound ET-1 is more 
difficult to dissociate from the ET B receptor in U373MG 
cells [19] and in porcine cerebellum [25] than bound 
antagonists such as PD142893 and Ro46-2005. As a result, 
the potency of these antagonists in inhibiting [125I]ET-1 or 
-3 binding decreases when the incubation time increases. 
From Fig. 1, it seems that bound ET-1 is also difficult to 
dissociate from the ET A receptor, and ET-I binding is 
mostly irreversible. It is of interest to know if the in- 
hibitory effects of ET A antagonists on ET-I binding is 
Table 1 
K i and IC5o values of ET receptor ligands against [125I]ET-1 binding in 
U138MG cells 
Ligand IC 50, Ki, Comments 
nM a nM a 
ET- 1 0.13 0.10 Non-selective 
FR139317 0.43 0.53 ET A selective 
BQI23 10.9 4.30 ET A selective 
PD 142893 31 22 Non-selective 
Ro46-2005 616 320 Non-selective 
IRL1620 > 1000 ND b ET B selective 
a The IC50 and K i values were calculated from Fig. 3B. Competition 
studies were performed by incubating membranes (0.02 mg) prepared 
from U138MG cells with 0.1 nM [)25I]ET-I in the presence of increasing 
concentrations of unlabeled ligarLds for 4 h at 25°C. Data were analyzed 
by using the radioligand binding analysis program 'EBDA and LIGAND'. 
b ND: not determined. 
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Fig. 4. Detection of ET receptor mRNA in U138MG cells or human 
placenta by RT-PCR. Total RNA was isolated from U138MG cells or 
human placenta and RT-PCR was conducted as described in Section 2. 
Samples were analyzed by ethidium bromide stained 1.2% agarose gel. 
Lane l: DNA size marker (1.0 kb DNA ladder, Gibco BRL); lane 2: 
U138MG RNA with ET A primers (Set 1); lane 3: human placenta RNA 
with ET A primers; lane 4: U138MG RNA without addition of ET A 
primers; lane 5: U138MG RNA without addition of reverse transcriptase; 
lane 6: U138MG RNA with ET B primers (Set 2); lane 7: human placenta 
RNA with ET B primers; lane 8: human placenta RNA without addition of 
ET B primers; lane 9: DNA size marker (EcoRI, HindlII digested A 
DNA). 
affected by the incubation time. We have compared the 
effects of ET-1, BQ123 and PD142893 on inhibiting 
[125I]ET-1 binding as a function of time. Competition 
studies were performed as in Fig. 3 except that three 
different incubation periods, 1 h, 8 h, and 24 h, were 
compared. Fig. 5 shows that, for both BQ123 and 
PD142893, the IC50 values increased when the incubation 
time was extended, although the change is more evident 
for PD142893 than for BQ123. In contrast, the IC50 value 
for ET-1 did not show a significant change with time. 
Table 2 summarizes the IC50 values for BQ123, PD142893 
and ET-1 determined at the chosen incubation time. These 
results suggest that, similar to ET B receptor, ET A receptor 
also exhibits irreversible binding characteristics and the 
potency of ET A antagonists in inhibiting [~25I]ET-1 binding 
decreases when the incubation time increases. 
We have shown that in human astrocytoma U373MG 
cells, the binding of ET-1 or ET-3 failed to show any 
effect on intracellular Ca 2 ÷ mobilization, arachidonic acid 
release, the formation of total inositol phosphates, or intra- 
cellular cAMP and cGMP levels [19]. However, we ob- 
served that ET B receptor in U373MG cells is very efficient 
in internalizing bound ET-1, consistent with the idea that 
ET B receptor seems to be involved in clearing ET by 
ligand-induced receptor internalization. Because of the sur- 
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Fig. 5. The effect of incubation time on the IC50 values. Membranes 
(0.01 mg) were incubated with 0.1 nM [125I]ET-1 in the presence of 
increasing concentrations of unlabeled ligands (A: ET-1, B: BQ123, C: 
PD142893) for 1 ( 0 ) ,  8 ( • ) ,  and 24 (O)  h at 25°C. Results are 
expressed as % of control (specific binding in the absence of unlabeled 
ligand). Non-specific binding, determined in the presence of 1 /zM of 
ET-1 was subtracted from total binding to give specific binding. Each 
value represents the mean of 2 determinations. 
Table 2 
IC5o values of ET-1 and antagonists at different incubation times 
Incubation ICs0, nM a 
time BQ123 PD142893 ET-1 
1 h 2 4 0.27 
8 h 11 24 0.27 
24 h 14 146 0.38 
a iC50 values were determined from Fig. 5. Competition studies were 
performed by incubating membranes (0.01 rag) prepared from U138MG 
cells with 0.1 nM [125I]ET-1 in the presence of increasing concentrations 
of unlabeled ligands at 25°C for 1, 8, and 24 h. 
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Fig. 6. The effects of ET-1 on PI hydrolysis and cAMP formation. (A) PI 
hydrolysis: cells were prelabeled with myo-[3H]inositol (1 /xCi/well) for 
16 h. Cells were challenged with various concentrations of ET-1 ( • )  or 
100 /zM of histamine (A)  in Buffer A with 10 mM LiC1 for 30 min at 
37°C. Results were calculated by normalizing AG1-X8-bound radioactiv- 
ity at each point to that of control (no addition of ET). Each value 
represents the mean+S.D,  of 3 determinations. (B) The formation of 
cAMP: cells were incubated with (black bar) or without (dotted bar) 1 
/xM ET-l+forskol in  or isoproterenol for 15 min at 37°C. Control 
(100%): no addition of ET-1 or test agents. The results of treating cells 
with ET-1 alone (hatched bar) at 10 nM and 1 /~M were also shown. 
Each value represents the mean + S.D. of 3 determinations. * * P < 0.01, 
• P < 0.05. Statistics were performed using the unpaired t-test in 
"StatView II' (Abacus Concepts, Inc. CA). 
prising observation that the U138MG cells express pre- 
dominantly the ET A receptor, we were curious to know if 
these cells would be different from the U373MG cells in 
terms of intracellular signaling and /or  agonist-induced 
receptor internalization. We found that, similar to the 
U373MG cells, ET-1 (10 -11 to 10 - 6  M) failed to stimu- 
late arachidonic acid release in U138MG cells (data not 
shown), although in control experiments ET-1 binding 
caused an increase in arachidonic acid release in human 
pericardial smooth muscle cells [26]. Interestingly, when 
total water-soluble inositol phosphates were measured, 
ET-1 caused a modest stimulation of phosphatidyl inositol 
hydrolysis in these cells with an ECs0 of 24 nM, while 
ET-1 failed to show any effect on the U373MG cells (Fig. 
6A). The effects of ET-1 on the intracellular cAMP level 
were also examined. Fig. 6B shows that ET-1 alone at 10 
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Fig. 7. Ligand-induced receptor internalization. (A) U138MG cells were incubated with 0.1 nM of [a251]ET-1 for different periods of time at 37°C. At the 
end of the incubation, cells were washed and treated with ice-cold 0.2 M acetic acid plus 0.5 M NaCI (pH 2.5). Total specific [125I]ET-1 binding (zx) and 
the amount of radioactivity resistant (internalized, A) and sensitive (surface bound, O) to acid-stripping were determined. (B) The percentage of 
radioactivity internalized was calculated from (A) by dividing acid-resistant binding by total specific binding. Each value represents the mean -t- S.D. of 3 
determinations. (C) and (D) Similar experiments were performed for U373MG cells (re-used with permission [19]). 
nM or 1 /zM failed to exhibit an effect on the cAMP level. 
Forskolin or isoproterenol alone stimulated the cAMP 
accumulation in a dose-dependent manner with forskolin 
showing a more profound effect. ET-1 (10 nM or 1 /zM) 
exhibited a consistent, yet statistically insignificant poten- 
tiating effect on either isoproterenol or forskolin-stimu- 
lated cAMP formation. 
As mentioned above, previously we have shown that 
ET-1 binding to U373MG astrocytoma cells results in 
rapid receptor internalization [19]. Receptor internalization 
has been implied to be an effective mechanism in peptide 
clearance [27]. It is of interest to know if U138MG, 
expressing predominantly ET A , would exhibit similar char- 
acteristics as the U373MG cells in internalizing bound 
ET-1. Fig. 7A,B shows that, in the U138MG cells, none of 
the bound ET-1 was internalized within the first 10 min of 
incubation. This percentage increased to 42% after 30 min 
of incubation. The percentage of internalization did not 
reach 81% until after 90 min of incubation. In contrast, 
when U373MG cells were incubated with 0.1 nM of 
[~25I]ET-1 at 37°C, 81% of bound ET-1 was internalized 
within the first 10 min of incubation. The internalized 
radioactivity increased to 92% after 40 min and remained 
at this level up to 120 min (Fig. 7C,D). For both U138MG 
and U373MG cells, the :rate of ligand-induced receptor 
internalization is changing throughout the incubation pe- 
riod until a plateau is reached. The fact that the rate of 
internalization changes following time is commonly ob- 
served, and is likely related to the numbers of ligands 
and/or  receptors as the rate-limiting factors in this pro- 
cess. These results suggest that the U138MG cells are less 
efficient in internalizing bound ET-1 in comparison to 
U373MG. 
4 .  D i s c u s s i o n  
Previously we have studied ET receptor in the human 
astrocytoma U373MG cells and found that U373MG cells 
contain predominantly the ET B receptor which is ex- 
tremely efficient in internalizing bound ET. In this report 
we extend the studies to the human astrocytoma U138MG 
cells. From the binding studies, we show that the ET 
receptor in U138MG cells was predominantly ET A. This 
observation is unexpected since previous studies [14-19] 
show that the astrocytes/astrocytoma cells contain pre- 
dominantly the ET B receptor. To further confirm our 
observation, RT-PCR was performed with RNA prepared 
from human placenta as a positive control. Our results 
indicate that indeed the U138MG cells express predomi- 
nantly the ET A receptor. 
As shown in the time course studies, bound ET-1 is 
difficult to dissociate (Fig. 1). It is important to note that, 
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because of the unique irreversible binding characteristics, 
ET-1 binding may not reach equilibrium under normal 
binding conditions and thus special consideration should 
be taken for analysis of ET binding data. However, for the 
purpose of comparing our results with others, we have 
employed binding conditions similar to that used by other 
laboratories, and have determined K D and Bma x by 
Scatchard analysis. Our results show that the human astro- 
cytoma U138MG cells contain ET A receptor with 27810 
binding sites/cell. Previous studies by Hama et al. [14] 
showed that the proliferating rat astrocytes have 230000 
ET binding sites/cell with ET B characteristics. Ehrenreich 
et al. [15] reported that 21 000 ET-3 binding sites/cell are 
found in primary rat astrocytes. In comparison, the human 
astrocytoma U373MG cells have 90 300 binding sites/cell 
with ET B characteristics [19]. 
It is now a well known phenomenon that the vasocon- 
stricting effect of ET is long-lasting [1] and bound [125I]ET 
is difficult to dissociate from ET receptors [25]. We have 
previously shown that, in ET B receptors, because of the 
irreversible binding characteristics of ET, the inhibitory 
effects of antagonists on ET-1 binding diminish after a 
prolonged incubation period [19,25]. In this report, we 
demonstrate that ET-1 bound to the human ET A receptor in 
the U138MG cells is also difficult to dissociate, and the 
inhibitory effects of BQ123 and PD142893 on ET-1 bind- 
ing also decrease when the incubation time is prolonged. 
The time-dependent decrease of the inhibitory effects of 
BQ123 and PD142893 is likely due to the fact that antago- 
nist binding is more reversible than agonist binding, as 
previously proposed by us from studying ET A receptor in 
the human smooth muscle cells [26]. However, more ques- 
tions remain to be answered. For example, why is antago- 
nist binding more reversible than agonist binding? Studies 
using site-directed mutagenesis and ETA/ET B chimeric 
receptors have suggested that antagonists and agonists may 
interact with the ET receptors at different determinants 
[28,29]. Regarding the irreversible binding characteristics 
of ET and the long-lasting biological responses elicited by 
ET, several hypotheses such as disulfide interchange in the 
ET receptor-ligand complex [30], continuous ET receptor 
externalization [31], or co-localization of ET receptor with 
caveolin in caveolae [32] have been proposed to explain 
the phenomenon. Despite various efforts from our group 
and from others, it is not clear why ET-1 binding is 
irreversible. More studies will be required to understand 
the exact mechanism for the irreversible binding of ET. 
To investigate the function of the ET A receptor in the 
U138MG cells, we have examined the intracellular signal- 
ing evoked by ET, and also studied ligand-induced recep- 
tor internalization. Previously we have found that ET 
binding does not stimulate C a  2 + mobilization, arachidonic 
acid release, or the formation of total inositol phosphates 
in the U373MG cells, but ET binding induces rapid inter- 
nalization of a majority of the ET B receptor in these cells, 
suggesting that ET B may play an important role in ligand 
clearance through receptor internalization. Recently 
Fukuroda et al. [33] employed the ET B selective antagonist 
BQ788 and the ET A selective antagonist BQ123 to demon- 
strate that ETa, but not ET A, is possibly involved in ET 
clearance. Our results show that the U138MG cells are less 
efficient in internalizing bound ET-1, consistent with the 
hypothesis that ET A may play a less important role in the 
clearance of ET-1. Interestingly, in U138MG cells, ET-1 
caused a modest stimulation in PI hydrolysis in these cells. 
We have previously shown that ET-1 stimulates PI hydrol- 
ysis through ET A receptor in the rat pituitary MMQ cell 
line [34]. More recently, we have found that, although 
human pericardial smooth muscle cells express both ET A 
and ET B receptors, the intracellular signaling is primarily 
mediated through the ET A receptor [26]. The present obser- 
vation further supports the notion that ET A is likely the 
receptor that is linked to signal transduction. 
U373MG and UI38MG are human astrocytoma cells 
established by tissue explants from malignant glioblastoma 
patients. Both cell lines are spindle-shaped cells. Previous 
studies have shown that both U373MG and U138MG cells 
express granulocyte colony stimulating factor after stimu- 
lation by IL-1/3 and TNF-c~ [35]. However, although U373 
cells stain positive for glial fibrillary acidic protein (GFAP), 
U138 cells do not [36]. It is generally accepted that 
GFAP-positive cell lines tend to express markers closest to 
those of differentiated astrocytes in situ. Is expression of 
GFAP related to changes in ET receptor subtype expres- 
sion? Information in this regard is rather limited. However, 
Hama et al. [14] have shown that, in rat astrocytes, dibu- 
tyryl cyclic AMP treatment causes the astrocytes to change 
into a differentiated state. Although they observe a marked 
increase in the expression of ET receptor, the receptor 
subtype remains ET B, suggesting that the expression of 
ET A or ET B may not be related to the differentiated state 
of the cells. Nevertheless, because ET receptor expression 
pattern can be quite different among species, this study 
may not be extrapolated to human astrocytes. Additional 
studies are required to address these issues. 
An important implication of the current study is that 
human astrocytoma cells, and/or  perhaps human astro- 
cytes, are able to express either ET A or ET B receptor, 
possibly dependent upon the pathophysiological condi- 
tions. Indeed Harland et al. [37] show that in normal 
human brains ET A receptor is localized within the meninges 
overlying the cerebral cortex, but is not found in the 
neuronal or glial cells, which express mainly the ET B 
receptor. In contrast, in patients with meningiomas, the 
distribution of ET A receptor is denser and more homoge- 
neous. As mentioned above, ET is synthesized by neurons, 
and has been proposed as a neurotransmitter/  
neuromodulator [l 1]. Considering that ET is such a potent 
agent in causing severe apnea and other cerebrovascular 
hemodynamic effects [38], it is conceivable that glial cells, 
especially astrocytes with a major role in maintaining 
neurons' signaling capacity by cleaning up neurotrans- 
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mitters and neuromodula tors  in the synapses,  will  have a 
'bu i l t - in '  m e c h a n i s m  to quickly  r e m o v e  ET  once  it is 
released.  Because  ET B, the ET  receptor  invo lved  in clear- 
ance, is the predominant  subtype in most  pr imary or  
establ ished culture of  astrocytic  cells, we have  therefore  
proposed  a hypothesis  that the major  funct ion of  ET  B 
receptor  in astrocytes is to c lear  ET f rom the neuronal  
environment .  Howeve r ,  under  certain pathological  condi-  
tions, ET A may  b e c o m e  the predominant  receptor  in astro- 
cytes and ET-1 c learance may  be impaired,  result ing in 
undesirable consequences .  At  present  it is unclear  what  is 
regulat ing the express ion o f  different  types of  ET receptor  
in the a s t r o c y t e s / a s t r o c y t o m a  cells. 
In conclusion,  f rom the binding studies and the R T - P C R  
results, we show that the lET receptor  in human astrocy- 
toma U 1 3 8 M G  cells is p redominant ly  ET A. ET-1 binding 
is o f  high affinity, and bound  ET  is difficult  to dissociate.  
ET-1 binding to these cells  causes a modes t  s t imulat ion in 
PI hydrolysis .  Finally,  the U 1 3 8 M G  cells are less eff ic ient  
in internal izing bound ET-1.  These  results suggest  that 
ET A in the astrocytes and as t rocytoma cells  is l ikely the 
receptor  l inked to signal transduction,  but  less eff ic ient  in 
clear ing ET-1.  
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